Leveraging JDQ443 to Face New Challenges & Utilize Opportunities in Treating KRAS G12C Mutant Cancers

Time: 4:00 pm
day: Conference Day Two


  • Elucidating the latest preclinical and clinical data on JDQ443, a promising inhibitor of KRAS G12C mutant cancer cells, resulting in improved therapeutic outcomes
  • Overcoming emerging mechanisms of resistance to KRAS G12C-targeted therapy and how JDQ443 offers a potential solution to overcoming these challenges
  • Advancing combination treatments to explore the opportunities for combining JDQ443 with other cancer drugs to enhance its effectiveness ultimately leading to better patient outcomes